期刊文献+

端粒、端粒酶与卵巢癌的诊治进展

暂未订购
导出
摘要 端粒长度是决定细胞增殖能力和寿命的分子标志 ,而端粒酶活化则是细胞恶化的共同通路。端粒酶是目前已知的最为广谱的肿瘤分子标记物 ,并可能成为肿瘤诊断和预后判断的新指标以及肿瘤治疗的新靶点。
出处 《国外医学(妇幼保健分册)》 2002年第3期121-122,共2页 Foreign Medical Sciences (Section of Maternal and Child Health)
  • 相关文献

参考文献15

  • 1[1]Harley CB, Villeponteau B. Telomeres and telomeras in aging and cancer[J]. Curropin Genet Dev,1995,5(2):249.
  • 2[2]Harly CB. Telomere loss:mitotic clock or genetic time bomb[J]? Mutat Res,1991,256:271-282.
  • 3[3]Kyo S, Kanaya T, Takakura, et al. Expression of human telomerase subunits in ovarian malignant,borderline and benign tumors[J]. Int J Cancer, 1999,5,80(6):804-809.
  • 4[4]Wan M, Li WZ, Duggan BD, et al. Telomerase activity in benign and malignant epithelial ovarian tumors[J]. J Natl Cancer Inst,1997,89(6):437-441.
  • 5[5]Kim NW, Piatyszek MA, Prouse KR, et al. Specific association of human telomerase activity with immortal cells and cancer[J]. Science,1994,266:2011-2015.
  • 6[6]Yokoyama Y, Takahashi Y, Shinohara A, et al. Telomerase activity in the female reproductive tract and neoplasms[J].Gynecol Oncol,1998,68(2):145-149.
  • 7[7]Murakami J, Nagai N, Ohama K, et al. Telomerase activity in ovarian tumors[J]. Cancer,1997,80(6):1085-1092.
  • 8[8]Kyo S, Takakura M, Tanaka M ,et al. Quantitative differences in telomerase activity among malignant,premalignant,and benign ovarian lesions[J].Clin Cancer Res, 1998,4(2):399-405.
  • 9[9]Kyo S, Kanaya T, Takakura M, et al. Expression of telomerase subunits in ovarian malignant,borderline and benign tumors[J]. Int J Cancer, 1999,80(6):804-809.
  • 10[10]Duggan BD, Wan M, Yu MC, et al. Detection of ovarian cancer cells:comparison of a telomerase assay and cytologic examination[J]. J Natl Cancer Inst,1998,90(3):238-242.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部